• 1.

    Au E, et al. Cancer in kidney transplant recipients. Nat Rev Nephrol 2018; 14:508520. doi: 10.1038/s41581-018-0022-6

  • 2.

    Howell M, et al. Eliciting patient preferences, priorities and trade-offs for outcomes following kidney transplantation: A pilot best-worst scaling survey. BMJ Open 2016; 6:e008163. doi: 10.1136/bmjopen-2015-008163

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 3.

    Lipson EJ, et al. Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma. J Clin Oncol 2014;32:e69-e71. doi: 10.1200/JCO.2013.49.2314

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 4.

    Lipson EJ, et al. Tumor regression and allograft rejection after administration of anti-PD-1. N Engl J Med 2016; 374:896898. doi: 10.1056/NEJMc1509268

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 5.

    Murakami N, et al. A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant. Kidney Int [published online ahead of print December 23, 2020]. doi: 10.1016/j.kint.2020.12.015; https://www.kidney-international.org/article/S0085-2538(20)31534-9/fulltext

    • Search Google Scholar
    • Export Citation
  • 6.

    Abdel-Wahab N, et al. Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: An institutional experience and a systematic review of the literature. J Immunother Cancer 2019; 7:106. doi: 10.1186/s40425-019-0585-1

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 7.

    Haslam A, Prasad V. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw Open 2019; 2:e192535. doi: 10.1001/jamanetworkopen.2019.2535

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 8.

    Krishnamoorthy S, et al. CAR-T therapy in solid organ transplant recipients with treatment refractory posttransplant lymphoproliferative disorder. Am J Transplant 2021; 21:809814. doi: 10.1111/ajt.16367

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 9.

    Mamlouk O, et al. Safety and efficacy of CAR T-cell therapy in kidney transplant recipients. Blood [published online ahead of print December 17, 2020]. doi: 10.1182/blood.2020008759; https://ashpublications.org/blood/article/doi/10.1182/blood.2020008759/474741/Safety-and-Efficacyof-CAR-T-Cell-Therapy-in

    • Search Google Scholar
    • Export Citation

Immunotherapy and Novel Cancer Target Therapies in Kidney Transplant Recipients with Cancer

  • 1 Naoka Murakami, MD, PhD, is an associate physician at the Division of Renal Medicine, Brigham and Women's Hospital, and Instructor of Medicine at Harvard Medical School, Boston, MA. Ala Abudayyeh, MD, is Associate Professor at the Division of Internal Medicine, Section of Nephrology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Restricted access
Save